Paper Details

  1. Home
  2. Paper Details

Futibatinib for <i>FGFR2</i>-Rearranged Intrahepatic Cholangiocarcinoma.

Author: , AbramsThomas A, AhnDaniel, BenhadjiKarim A, BridgewaterJohn A, CassierPhilippe A, ChangHeung-Moon, ChenLi-Tzong, EpsteinRobert S, FuYao, FuruseJunji, GoyalLipika, HalimAbdel-Baset, HeYaohua, HollebecqueAntoine, KarasicThomas B, KelleyRobin K, KlümpenHeinz-Josef, KomatsuYoshito, LiuMei, MahipalAmit, MasudaKunihiro, Meric-BernstamFunda, MitchellEdith P, MoehlerMarkus, MorizaneChigusa, OhDo-Youn, SalimiTehseen, TaberneroJosep, ValleJuan W, WacheckVolker

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Alterations in fibroblast growth factor receptor 2 (FGFR2) are promising drug targets for intrahepatic cholangiocarcinoma. Futibatinib, a next-generation FGFR inhibitor, has shown antitumor activity in patients with FGFR-altered tumors and preclinical activity against acquired resistance mutations.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">Alterations in fibroblast growth factor receptor 2 (<i>FGFR2</i>) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding FGFR1-4 inhibitor, has been shown to have both anti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2206834

データ提供：米国国立医学図書館（NLM）

Futibatinib: A New Oasis for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma, a rare and aggressive cancer, is a formidable challenge for medical professionals. It's like a hidden desert well, difficult to locate and even more difficult to access. This study focused on the potential of futibatinib, a next-generation FGFR inhibitor, as a treatment for intrahepatic cholangiocarcinoma with FGFR2 rearrangements. Their research showed that futibatinib demonstrated promising antitumor activity in patients with FGFR-altered tumors, offering hope for a more effective treatment option. This discovery is like finding a hidden oasis in the vast and unforgiving desert of cancer research.

Futibatinib: A Promising New Weapon in the Arsenal

The study found that futibatinib exhibited strong preclinical activity against acquired resistance mutations associated with ATP-competitive FGFR inhibitors. This suggests that futibatinib could potentially overcome resistance to existing FGFR inhibitors, making it a valuable tool for treating patients with FGFR2-rearranged intrahepatic cholangiocarcinoma. It's like finding a new, sharper tool for digging in the desert, allowing us to reach the water source more effectively.

Fighting Cancer: A Journey of Persistence

The fight against cancer is a constant battle, and finding new and effective treatments is essential. This study highlights the importance of research and innovation in the fight against cancer. It's like a tireless camel caravan, traversing the desert in search of a cure, never giving up hope. The journey may be long and arduous, but with determination and persistence, we can find new oases of hope for those affected by this devastating disease.

Dr. Camel's Conclusion

Futibatinib offers a beacon of hope for patients with FGFR2-rearranged intrahepatic cholangiocarcinoma. It's like a new wellspring of water in the desert, offering a lifeline to those who need it most.

Date :
  1. Date Completed 2023-01-23
  2. Date Revised 2023-10-27
Further Info :

Pubmed ID

36652354

DOI: Digital Object Identifier

10.1056/NEJMoa2206834

Related Literature

Article Analysis
・Effects of futibatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.